Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients from 12 Randomized Trials

Circulation

5 Giugno Giu 2020 one month ago
  • Bartorelli A, Trabattoni D

New randomized controlled trials (RCTs) have become available on oral P2Y12 inhibitors in acute coronary syndrome (ACS). We aimed to evaluate current evidence comparing the efficacy and safety profile of prasugrel, ticagrelor and clopidogrel in ACS by a meta-analysis of RCTs.

Reference

Navarese EP, Khan SU, Kołodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients from 12 Randomized Trials. Circulation 2020 May 29. doi: 10.1161/CIRCULATIONAHA.120.046786

Go to PubMed